Zi Yingxin, Ji Meiqi, Deng Yu, Qin Yali, Wang Rui, Meng Huan, Jin Ming
Beijing University of Chinese Medicine.
Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.
Medicine (Baltimore). 2019 Apr;98(15):e15178. doi: 10.1097/MD.0000000000015178.
Dry eye (DE) is a common type of ocular surface disease that affects many people. Moxibustion has been widely used in China to treat ocular surface diseases, especially DE. Many clinical trials have demonstrated that moxibustion can increase the tear secretion quantity and improve tear film stability. The purpose of this review is to provide an objective and normative systematic review to evaluate the effectiveness and safety of moxibustion treatment in patients with DE.
The systematic review will include all of the randomized controlled trials on the effectiveness and safety of moxibustion for DE. Nine medical databases, namely PubMed, EMBASE, the Cochrane Library, Google Scholar, Web of Science, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal database (VIP), Wanfang Database, and CBM, will be searched from the date of the database inception to February 28, 2019. We will also search registers of clinical trials, potential gray literature, and conference abstracts. There are no restrictions on language and publication status. Two reviewers will independently select studies, and extract and manage data. The reporting quality and risk of bias will be assessed by other 2 review authors. The primary outcomes will include ocular surface disease index (OSDI) scores, Schirmer test (SIT) results, tear meniscus height (TMH), and tear break-up time (TBUT) values. Quality of life, the main symptom scores before and after treatment, meibomian gland (MG) morphology, total treatment efficacy, and safety will be evaluated as the secondary outcomes. We will use RevMan V.5.3 software to synthesize and analyze data.
This systematic review will provide a comprehensive review of current evidence of moxibustion for DE from the following aspects: the OSDI, SIT, TMH, BUT, quality of life, the main symptom scores, MG morphology, total treatment efficacy, and safety.
The conclusion of our systematic review will provide evidence to determine whether moxibustion is an effective and safe intervention for patients with DE.
Since patients will not be involved in this study, it is not necessary to obtain ethical approval. The protocol and results will be published in a peer-reviewed journal.
PROSPERO CRD42018097399.
干眼(DE)是一种常见的眼表疾病,影响着众多人群。艾灸在中国已被广泛用于治疗眼表疾病,尤其是干眼。许多临床试验表明,艾灸可增加泪液分泌量并改善泪膜稳定性。本综述的目的是提供一项客观且规范的系统评价,以评估艾灸治疗干眼患者的有效性和安全性。
该系统评价将纳入所有关于艾灸治疗干眼有效性和安全性的随机对照试验。将从数据库创建之日起至2019年2月28日,检索九个医学数据库,即PubMed、EMBASE、Cochrane图书馆、谷歌学术、科学引文索引、中国知网、维普中文科技期刊数据库、万方数据库和中国生物医学文献数据库。我们还将检索临床试验注册库、潜在的灰色文献和会议摘要。对语言和发表状态无限制。两名评审员将独立选择研究,并提取和管理数据。报告质量和偏倚风险将由另外两名评审作者评估。主要结局将包括眼表疾病指数(OSDI)评分、泪液分泌试验(SIT)结果、泪河高度(TMH)和泪膜破裂时间(TBUT)值。生活质量、治疗前后主要症状评分、睑板腺(MG)形态、总治疗效果和安全性将作为次要结局进行评估。我们将使用RevMan V.5.3软件对数据进行综合分析。
本系统评价将从以下方面对当前艾灸治疗干眼的证据进行全面综述:OSDI、SIT、TMH、BUT、生活质量、主要症状评分、MG形态、总治疗效果和安全性。
我们系统评价的结论将为确定艾灸对干眼患者是否为有效且安全的干预措施提供证据。
由于患者不参与本研究,无需获得伦理批准。方案和结果将发表在同行评审期刊上。
PROSPERO注册号:PROSPERO CRD42018097399。